RESILIENCE GOVERNMENT SERVICES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1999-01-01

Employees: 251

Market Cap: -

Website: https://www.ologybio.com

Clinical Trials

Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder

Not Applicable

Completed

Conditions: Post Traumatic Stress Disorder

Interventions: Drug: PRX-03140

First Posted Date: 2011-12-15

Last Posted Date: 2014-09-25

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 7

Registration Number: NCT01492699

Locations: 🇺🇸
Sarkis Clinical Trials, Gainesville, Florida, United States

H5N1 Vaccine Study in Japanese Adults

Phase 2

Completed

Conditions: H5N1 Influenza

Interventions: Biological: H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)

First Posted Date: 2011-06-27

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 340

Registration Number: NCT01382329

Locations: 🇯🇵
Medical Co. LTA PS Clinic, Fukuoka-shi, Fukuoka-Ken, Japan
🇯🇵
Osaka Pharmacology Clinical Research Hospital, Osaka-shi, Osaka-Fu, Japan
🇯🇵
CPC Clinic, Medipolis Medical Research Institute, Kagoshima-shi, Kagoshima-Ken, Japan

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine

First Posted Date: 2011-03-22

Last Posted Date: 2023-02-16

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 353

Registration Number: NCT01320696

Locations: 🇺🇸
Accelovance, Rockville, Maryland, United States

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Phase 1

Completed

Conditions: Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

Interventions: Drug: GelVac™ nasal powder H5N1 influenza vaccine.
Drug: Placebo

First Posted Date: 2010-12-10

Last Posted Date: 2017-02-02

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 7

Registration Number: NCT01258062

Locations: 🇺🇸
Florida Research Network, LLC, Gainesville, Florida, United States

Ross River Virus (RRV) Vaccine Study

Phase 3

Completed

Conditions: Prophylaxis of Ross River Virus Infection

Interventions: Biological: Ross River Virus Vaccine

First Posted Date: 2010-11-17

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 1968

Registration Number: NCT01242670

Locations: 🇦🇺
Holdsworth House, Byron Bay, New South Wales, Australia
🇦🇺
Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia
🇦🇺
St. Vincents Hospital, Darlinghurst, New South Wales, Australia

and more 13 locations

Yearly Strain Variation Study, 2010/2011

Phase 3

Completed

Conditions: Seasonal Influenza
Influenza

Interventions: Biological: Inactivated influenza vaccine (split virus, Vero cell-derived)

First Posted Date: 2010-07-07

Last Posted Date: 2020-10-22

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 110

Registration Number: NCT01157702

Locations: 🇦🇹
University Clinic for Clinical Pharmacology, General Hospital Vienna, Vienna, Austria

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)

First Posted Date: 2010-02-05

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 211

Registration Number: NCT01063088

Locations: 🇦🇹
Sanatorium Leech, Graz, Austria
🇧🇪
ZU Gent, Centrum voor vaccinologie, Ghent, Belgium

Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents

Phase 1

Completed

Conditions: Influenza, Avian

Interventions: Biological: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation

First Posted Date: 2010-01-20

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 684

Registration Number: NCT01052402

Locations: 🇸🇬
Mount Elizabeth Medical Centre, The Child and Allergy Clinic, Singapore, Singapore
🇪🇸
Centro de Salud de Paiporta, Paiporta, Spain
🇪🇸
Instituto Hispalense de Pediatria, Pediatría - IHP1, Sevilla, Spain

and more 17 locations

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Phase 1

Completed

Conditions: Influenza
Pandemic Influenza

Interventions: Biological: H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)
Biological: Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011

First Posted Date: 2009-09-14

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 400

Registration Number: NCT00976469

Locations: 🇩🇪
General Practice, Mönchengladbach, Germany
🇦🇹
Allgemeines Krankenhaus (AKH) der Stadt Wien (General Hospital Vienna), Vienna, Austria

A/H1N1 Immunogenicity and Safety in Adults

Phase 1

Completed

Conditions: Pandemic Influenza
Influenza

Interventions: Biological: H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)

First Posted Date: 2009-08-14

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 408

Registration Number: NCT00959465

Locations: 🇦🇹
University Hospital, Department of Clinical Pharmacology, Vienna, Austria
🇩🇪
Praxis Regner Schmitt, Mainz, Germany
🇦🇹
Sanatorium Leech, Graz, Austria

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy